EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Intercept Pharmaceuticals's Enterprise Value is $327.2 Mil.
Intercept Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 was $-58.8 Mil. Therefore, Intercept Pharmaceuticals's EV-to-FCF for today is -5.56.
The historical rank and industry rank for Intercept Pharmaceuticals's EV-to-FCF or its related term are showing as below:
ICPT'
s EV-to-FCF Range Over the Past 10 Years
Min: -297.08 Med: -12.66 Max: 299.69
Current: -5.56
During the past 13 years, the highest EV-to-FCF of Intercept Pharmaceuticals was 299.69. The lowest was -297.08. And the median was -12.66.
ICPT's EV-to-FCF is ranked worse than 100% of 401
companies
in the Biotechnology industry
Industry Median: 2.07
vs ICPT: -5.56
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2023-05-29), Intercept Pharmaceuticals's stock price is $10.26.
Intercept Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $6.280. Therefore, Intercept Pharmaceuticals's PE Ratio for today is 1.63.
Competitive Comparison
For the Biotechnology subindustry, Intercept Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercept Pharmaceuticals EV-to-FCF Distribution
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's EV-to-FCF falls in comparison to its industry or sector. The grey bar indicates the EV-to-FCF's extreme value range as defined by GuruFocus.
Intercept Pharmaceuticals EV-to-FCF Calculation
Intercept Pharmaceuticals's EV-to-FCF for today is calculated as:
Intercept Pharmaceuticals's current Enterprise Value is $327.2 Mil.
Intercept Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-58.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Intercept Pharmaceuticals's PE Ratio for today is calculated as:
Intercept Pharmaceuticals's share price for today is $10.26.
Intercept Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.280.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Intercept Pharmaceuticals EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Intercept Pharmaceuticals (NAS:ICPT) Business Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.51(5.23%) Volume: 1,489,063 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
ICPT has been successfully added to your 